Published in Transplantation on July 15, 2006
Living-donor liver transplantation and hepatitis C. HPB Surg (2013) 0.90
Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors. Antimicrob Agents Chemother (2008) 0.88
Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation. Med Microbiol Immunol (2009) 0.87
G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence. World J Gastroenterol (2009) 0.82
Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future. World J Gastroenterol (2014) 0.81
Hepatitis C virus reinfection after liver transplantation: is there a role for direct antiviral agents? World J Gastroenterol (2014) 0.81
Liver transplantation and hepatitis C. Int J Hepatol (2012) 0.79
Antiviral treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon. Dig Dis Sci (2009) 0.78
Hepatitis C virus reinfection after liver transplant: New chances and new challenges in the era of direct-acting antiviral agents. World J Hepatol (2015) 0.76
Successful Anti-HCV Therapy of a Former Intravenous Drug User with Sofosbuvir and Daclatasvir in a Peritranspant Setting: A Case Report. Am J Case Rep (2016) 0.75
Treatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug Therapy. J Clin Transl Hepatol (2016) 0.75
Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney disease. Therap Adv Gastroenterol (2016) 0.75
Prevention of hepatitis C recurrence after liver transplantation: An update. World J Gastrointest Pharmacol Ther (2012) 0.75
Slower Fibrosis Progression Among Liver Transplant Recipients With Sustained Virological Response After Hepatitis C Treatment. Gastroenterology Res (2015) 0.75
Pretransplant serum hepatitis C virus RNA levels predict response to antiviral treatment after living donor liver transplantation. PLoS One (2013) 0.75
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA (2007) 14.54
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology (2010) 7.86
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med (2005) 7.18
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med (2007) 5.13
Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology (2009) 4.03
Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet Neurol (2008) 3.81
Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology (2004) 3.70
Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol (2004) 3.56
Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA (2013) 3.46
Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology (2006) 3.18
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med (2015) 3.13
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology (2010) 3.02
New staging system and a registry for perihilar cholangiocarcinoma. Hepatology (2011) 2.89
Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J Clin Invest (2010) 2.87
Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology (2006) 2.68
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology (2003) 2.64
Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. Nat Genet (2007) 2.48
Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology (2012) 2.42
Senescence rates are determined by ranking on the fast-slow life-history continuum. Ecol Lett (2008) 2.30
Adjuvant therapy in pancreatic cancer: a critical appraisal. Drugs (2007) 2.26
Biliary reconstruction using a side-to-side choledochocholedochostomy with or without T-tube in deceased donor liver transplantation: a prospective randomized trial. Ann Surg (2009) 2.19
Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology (2005) 2.19
Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol (2012) 2.15
Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med (2012) 2.14
Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection. Hepatology (2013) 2.13
Polymorphisms in melanoma differentiation-associated gene 5 link protein function to clearance of hepatitis C virus. Hepatology (2015) 2.11
Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol (2010) 2.09
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl (2007) 2.08
Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation--a randomized, double-blind trial. Am J Transplant (2005) 2.08
Different cava reconstruction techniques in liver transplantation: piggyback versus cava resection. Hepatobiliary Pancreat Dis Int (2014) 2.08
The common I148 M variant of PNPLA3 does not predict fibrosis progression after liver transplantation for hepatitis C. Hepatology (2011) 2.08
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol (2011) 2.06
Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg (2009) 2.06
Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology (2008) 2.03
Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl (2003) 2.01
Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany--limitations of the 'sickest first'-concept. Transpl Int (2010) 1.99
First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. Hum Mol Genet (2008) 1.98
3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. Lancet (2006) 1.97
Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transpl (2011) 1.92
Long-term survival and predictors of relapse after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl (2007) 1.91
Effect of enteral nutrition and synbiotics on bacterial infection rates after pylorus-preserving pancreatoduodenectomy: a randomized, double-blind trial. Ann Surg (2007) 1.90
A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis. Nat Genet (2006) 1.90
The surgical treatment of bilateral benign nodular goiter: balancing invasiveness with complications. Dtsch Arztebl Int (2014) 1.88
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut (2012) 1.86
Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology (2002) 1.85
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology (2010) 1.79
Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology (2007) 1.79
Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology (2009) 1.79
Incidence of and risk factors for ischemic-type biliary lesions following orthotopic liver transplantation. Transpl Int (2009) 1.77
Hepatic artery thrombosis after adult liver transplantation. Liver Transpl (2003) 1.74
Omega-3 fatty acids alleviate chemically induced acute hepatitis by suppression of cytokines. Hepatology (2007) 1.73
Assistance of microbial glycolipid antigen processing by CD1e. Science (2005) 1.73
Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology (2011) 1.71
Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology (2011) 1.70
Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS (2006) 1.68
Trends and experiences in liver retransplantation over 15 years. Liver Transpl (2007) 1.66
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol (2008) 1.65
Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology (2010) 1.65
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol (2010) 1.63
Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology (2011) 1.62
Reactivation of viral replication after replacement of tenofovir by adefovir. Hepatology (2005) 1.60
Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology (2003) 1.59
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Diagnosis and treatment of arterial steal syndromes in liver transplant recipients. Liver Transpl (2003) 1.58
Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis (2013) 1.58
Production of pluripotent stem cells by oocyte-assisted reprogramming: joint statement with signatories. Natl Cathol Bioeth Q (2005) 1.57
Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation (2002) 1.57
Extracorporeal liver perfusion as hepatic assist in acute liver failure: a review of world experience. Xenotransplantation (2002) 1.57
Sex is a major determinant of CYP3A4 expression in human liver. Hepatology (2003) 1.57
Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis. Liver Int (2011) 1.57
Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl (2006) 1.56
Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes. J Hepatol (2012) 1.56
Pregnancy in primary sclerosing cholangitis. Gut (2011) 1.55
Soluble urokinase plasminogen activator receptor is associated with progressive liver fibrosis in hepatitis C infection. J Clin Gastroenterol (2012) 1.53
Distinct, alcohol-modulated effects of PNPLA3 genotype on progression of chronic hepatitis C. J Hepatol (2011) 1.52
Hepatitis C recurrence and fibrosis progression are not increased after living donor liver transplantation: a single-center study of 289 patients. Liver Transpl (2007) 1.49
Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol (2005) 1.49
Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res (2003) 1.48